Related Experiment Video
Updated: Jul 11, 2026

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
Published on: December 21, 2019
Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp
Felipe Diaz-Griffero1, Alak Kar, Mark Lee
1Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Department of Pathology, Division of AIDS, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
The restriction factors, TRIM5alpha in most primates and TRIMCyp in owl monkeys, block infection of various retroviruses soon after virus entry into the host cell. Rhesus monkey TRIM5alpha (TRIM5alpha rh) inhibits human immunodeficiency virus (HIV-1) and feline immunodeficiency virus (FIV) more potently than human TRIM5alpha (TRIM5alpha hu). TRIMCyp restricts infection of HIV-1, simian immunodeficiency virus of African green monkeys (SIV agm) and FIV. Early after infection, TRIMCyp, like TRIM5alpha rh and TRIM5alpha hu, decreased the amount of particulate viral capsid in the cytosol of infected cells. The requirements for the TRIMCyp and TRIM5alpha domains in restricting different retroviruses were investigated. Potent restriction of FIV by TRIMCyp occurred in the complete absence of RING and B-box 2 domains; by contrast, efficient FIV restriction by TRIM5alpha rh required these domains. Variable region 1 of the TRIM5alpha rh B30.2 domain contributed to the potency of HIV-1, FIV and equine infectious anemia virus restriction. Thus, although differences exist in the requirements of TRIMCyp and TRIM5alpha for RING/B-box 2 domains, both restriction factors exhibit mechanistic similarities.
Insights
TRIM5alpha and TRIMCyp are restriction factors that block retroviral infections. Their distinct domain requirements highlight mechanistic similarities and differences in antiviral activity against viruses like HIV-1 and FIV.
Area of Science:
- Virology
- Immunology
- Genetics
Background:
- Restriction factors TRIM5alpha (primates) and TRIMCyp (owl monkeys) inhibit retroviral entry.
- TRIM5alpha from rhesus monkeys (TRIM5alpha rh) is more potent against HIV-1 and FIV than human TRIM5alpha (TRIM5alpha hu).
- TRIMCyp restricts HIV-1, SIV agm, and FIV, reducing viral capsid levels post-entry.
Purpose of the Study:
- To investigate the domain requirements of TRIMCyp and TRIM5alpha in restricting different retroviruses.
- To compare the mechanisms of action between TRIMCyp and TRIM5alpha.
Main Methods:
- Comparative analysis of TRIMCyp and TRIM5alpha domain functions.
- Assessment of retroviral restriction potency by different TRIM variants.
- Investigation of specific TRIM domains, including RING, B-box 2, and B30.2 variable region 1.
Main Results:
- TRIMCyp potently restricted FIV without RING and B-box 2 domains, unlike TRIM5alpha rh which required them.
- Variable region 1 of TRIM5alpha rh's B30.2 domain enhanced restriction of HIV-1, FIV, and equine infectious anemia virus.
- Both TRIMCyp and TRIM5alpha reduced cytosolic viral capsid levels early in infection.
Conclusions:
- TRIMCyp and TRIM5alpha share mechanistic similarities in retroviral restriction despite differing domain requirements.
- Specific domains, like TRIM5alpha rh's B30.2 variable region 1, play crucial roles in antiviral potency.
- Understanding these factors provides insights into host-pathogen interactions and viral evasion strategies.
Related Concept Videos
Retroviruses
LTR Retrotransposons
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
Non-LTR Retrotransposons
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly

